search
Back to results

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)

Primary Purpose

Gastric Cancer

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Bemarituzumab
Placebo
Modified FOLFOX6
Sponsored by
Five Prime Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1
  • Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay
  • Candidate for mFOLFOX6 chemotherapy

Key Exclusion Criteria:

  • Untreated or symptomatic central nervous system (CNS) metastases
  • Clinically significant cardiac disease,
  • Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2
  • Active infection requiring systemic treatment
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection
  • Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway
  • Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer
  • Known positivity for human epidermal growth factor receptor 2 (HER2)
  • Women who are pregnant or breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Sites / Locations

  • University of Arizona Cancer Center
  • The Oncology Institute of Tuscon
  • Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc
  • Sutter Medical Group
  • UCLA Medical Centre - Santa Monica Hematology and Oncology
  • Innovative Clinical Research Institute (ICRI)
  • Yale Cancer Center
  • Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut
  • University of Chicago
  • Northwestern Medicine Cancer Center Warrenville
  • University of Kansas Medical Center
  • Oschsner Clinic Foundation
  • Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
  • University of Michigan Health System
  • Karmanos Cancer Institute
  • Josephine Ford Cancer Center-Henry Ford Cancer Center
  • Summit Medical Group. Morristown Oncology
  • University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
  • Stony Brook Cancer Center
  • Westchester Institute For Treatment Of Cancer & Blood Disorders
  • UNC- Chapel Hill
  • FirstHealth Outpatient Cancer Center
  • St. Luke's Physician Group - St. Luke's Cancer Care Associates
  • Medical University of South Carolina
  • Tennessee Cancer Specialists
  • Arlington Cancer Center
  • Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center
  • Virginia Mason Seattle Main Clinic
  • Chris O'brien Lifehouse
  • The Townsville Hospital
  • Sydney Adventist Hospital
  • AZ Sint Jan
  • CH de l'Ardenne
  • CHC Clinique Saint-Joseph
  • CHU UCL Namur, site Godinne
  • Anhui Provincial Cancer Hospital
  • Shiyan Taihe Hospital
  • Wuhan Union Hospital of China
  • The 81st Hospital of Chinese PLA
  • Beijing Cancer Hospital
  • Chinese PLA General Hospital
  • The First Hospital of Jilin University
  • Sino Japanese Friendship Hospital of Jilin University
  • Hunan Cancer Hospital
  • Xiangya Hospital of Central South University
  • Chongqing Daping Hospital
  • Fujian Cancer Hospital
  • The First Affiliated Hospital, Zhejiang University
  • Sir Run Run Shaw Hospital
  • Zhejiang Cancer Hospital
  • Harbin Medical University Cancer Hopsital
  • Nanton Tumor Hospital
  • Shanghai East Hospital
  • Fudan University Shanghai Cancer Center
  • Ruijin Hospital Affiliated to Shanghai Jiatong University School of Medicine
  • Cancer Hospital of Shantou University Medical College
  • Liaoning Cancer Hospital
  • Fourth Hospital of Hebei Medical University
  • The Second Affiliated Hospital of Soochow University
  • Tianjin Medical University Cancer Institute and Hospital
  • Henan Cancer Hospital
  • CHRU Jean MINJOZ
  • Chu Morvan - Institut de Cancerologie
  • Hopital Nord France Comte - Site Le Mittan
  • Polyclinique de Gentilly
  • CHU de Saint Etienne
  • Centre de Radiotherapie - Clinique Sainte Anne
  • Centre Paul Strauss
  • Klinik fur Innere Medizin, Shwerpunkt Gastroenterologie, Hamatologie, Onkologie, Nephrologie
  • Stadtisches Klinikum Braunschweig
  • Krankenhaus Nordwest gGmbH, Institut fur Klinisch-Onkologische Forschung
  • Klinikum Ludwigsburg
  • Universitatsmedizin Manheim, II. Medizinische Klinik
  • Klinikum Ostalb, Stauferklinikum Schwabisch Gmund, Zentrum fur Innere Medizin
  • Kliniken Nordoberpfalz AG, Klinikum Weiden, Medizinische Klinik I
  • National Institute of Oncology
  • Del-Pesti Centrumkorhaz - Orszangos Hematologiai es Infektologiai Intezet, Onkologiai Osztaly
  • Sugarterapias es Klinikai Onkologaiai Intezet B-A-Z Megyei Korhaz
  • Josa Andras Teaching Hospital
  • University of Pecs, Clinic of Oncotherapy
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet
  • AOU Ospedall Riuniti Umberto
  • AO "S.G. Moscati"
  • Centro di Riferimento Oncologico
  • Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
  • Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS di Candiolo
  • Azienda Socio-Sanitaria Territoriale di Cremona
  • Azienda Ospedaliero Universitaria Caregg - I S.O.D. Oncologia Medica
  • Ospedale Policlinico S. Martino
  • Ospedale Generale Mater Salutis" - Azienda ULSS n. 21 di Legnago
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
  • Istituto Europeo di Oncologia
  • Servizio Oncologia Medica ed Ematologia, AOU dell'Universita
  • Fondazione Irccs Policlinico San Matteo
  • Azienda Ospedaliera Universitaria Pisana
  • Policlinico Universitario Campus Bio-Medico di Roma
  • Fondazione IRCSS Casa Sollievo Della Sofferenza
  • ASST della Valtellina e dell'Alto Lario - PO di Sondrio
  • A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
  • Azienda Sanitaria Universitaria Integrata de Udine
  • National Cancer Center Hospital East
  • Kagawa University Hospital
  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
  • Hiroshima Citizens Hospital
  • St. Marianna University School of Medicine Hospital
  • Japan Community Health Care Organization Kyushu Hospital
  • The Cancer Institute Hospital of JFCR
  • Niigata Cancer Center Hospital
  • Hyogo College of Medicine College Hospital
  • Osaka General Medical Center
  • Osaka Medical College Hospital
  • Gangnam Severance Hospital, Yonsei University Health System
  • Hallym University Sacred Heart Hospital
  • Seoul National University Bundang Hospital
  • Ajou University Hospital
  • Chonbuk National University Hospital
  • Gachon University Gil Medical Center
  • Kyungpook National University Chilgok Hospital
  • Dong-A University Hospital
  • Chungnam National University Hospital (CNUH)
  • Korea University Anam Hospital
  • Yonsei University Health System
  • Kangbuk Samsung Hospital
  • Asan Medical Center
  • The Catholic University of Korea, Seoul St. Mary's Hospital
  • Korea University Guro Hospital
  • Seoul National University Hospital
  • Beskidzkie Centrum Onkologii - Szpital Miejski im. Jana Pawla II w Bielsku-Bialej
  • Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
  • SP ZOZ Ministerstwa Spraw Wewnetrznych z Warminsko - Mazurskim Centrum Onkologii
  • Europejskie Centrum Zdrowia Otwock Szpital im. F. Chopina
  • Lekarz Beata Madej Mruk I Partner. Spolka Partnerska Oddzial nr 1 w Rzesowie
  • Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny Ministerstwa Obronty Narodowej
  • Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Onkologi I Radioterapii
  • Centro Hospitalar do Baixo Vouga, EPE
  • Hospital de Braga
  • Hospital Senhora Da Oliveira EPE
  • Centro Hospitalar Universitario do Porto E.P.E
  • Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E
  • Centro Hospitalar de Entre o Douro e Vouga EPE
  • Unidade Local de Saude de Matosinhos EPE
  • Institutul Clinic Fundeni - Clinica Pediatrie
  • S.C. Medisprof S.R.L
  • Institutul Oncologic, Prof. Dr. I. Chiricuta Cluj-Napoca
  • Spitalul Clinic Judetean de Urgenta ,,Sf. Apostol Andrei" Constanta, Clinica Oncologie Medicala
  • S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala
  • SC Oncolab SRL, Oncologie
  • S.C. Oncocenter Oncologie Clinica S.R.L
  • Complejo Hospitalario Universitario A Coruna
  • Hospital Universitario Fundacion Alcorcon
  • Hospital del Mar
  • Hospital Duran I Reynals - Instituto Catalan de Oncologia
  • Hospital de la Santa Creu I Sant Pau
  • Hospital General de Catalunya
  • Institut Catala d'Oncologia - Hospital Doctor Josep Trueta
  • Hospital Universitari Arnau de Vilanova
  • Hospital Universitario Fundacion Jimenez Diaz
  • Hospital Universitario HM Sanchinarro
  • Hospital General Universitario Gregorio Maranon
  • Hospital Universitario Puerta de Hierro Majadahonda
  • Clinica Universidad de Navarra
  • Complejo Hospital De Navarra
  • Corporacio Sanitaria Parc Tauli
  • Hosptial Universitario Virgen Macarena
  • Hospital Universitario Mutua de Terrassa
  • China Medical University Hospital
  • Faculty of Medicine, Chulalongkorn University
  • Chiangrai Prachanukroh Hospital
  • Faculty of Medicine, Prince of Sonkla University
  • Khon Kaen Hospital
  • Lampang Cancer Hospital
  • Cukurova University Faculty of Medicine Paediatric Nephrology
  • Hacettepe Universitesi Tip Fakultesi
  • Ankara Oncology Education and Research Hospital
  • Ondokuz Mayis University Medicine Faculty
  • Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi
  • Uludag Universitesi Tip Fakultesi
  • Gaziantep Universitesi Tip Fakultesi, Sahinbey Onkoloji Hastanesi
  • Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
  • Istanbul Madeniyet Universitesi Tip Fakultesi
  • Istanbul University Cerrahpasa Medical Faculty
  • Medical Park Izmir Hastanesi
  • Ege University Hopsital
  • Kocaeli Universitesi Tip Fakultesi
  • Inonu Universitesi Tip Fakultesi Turgut Ozal Tip Merkezi
  • Yuzuncuyil Universitesi Tip Fakultesi
  • Ninewells Hospital and Medical School

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Bemarituzumab + mFOLFOX6

Placebo + mFOLFOX6

Arm Description

Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.

Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.

Outcomes

Primary Outcome Measures

Progression-Free Survival (PFS)
PFS was defined as time from randomization until the date of radiographic disease progression based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death from any cause, whichever came first. PFS was analyzed using Kaplan-Meier methods. Participants with no progression or death, or who started new anticancer therapy before documented progression or death without documented progression, or who had ≥ 2 consecutive missing tumor assessments before documented progression or death without documented progression were censored on the date of last adequate tumor assessment. Participants with no baseline tumor assessment, were censored at the date of randomization. The primary efficacy analysis was pre-specified to be conducted after at least 84 PFS events were observed.

Secondary Outcome Measures

Overall Survival (OS)
OS is defined as time from randomization until death from any cause. Participants who were lost to follow-up or did not have a date of death were censored at the last date that they were known to be alive. Participants with confirmed death or alive status after the data cutoff date were censored at the data cutoff date. Median OS was estimated using a Kaplan-Meier analysis.
Overall Response Rate (ORR)
Tumor response assessment was performed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines. ORR is defined as the percentage of participants who achieved a best overall response (BOR) of either complete response (CR) or partial response (PR) based on investigator assessment of tumor lesions per RECIST v1.1. CR was defined as the disappearance of all lesions except lymph node short axis < 10 mm; PR was defined as a ≥ 30% reduction in sum of diameters in target lesions.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs are defined as adverse events (AEs) that started or worsened from the start of study drug to 28 days after permanent discontinuation of study drug. A serious AE is defined as any untoward medical occurrence that: Resulted in death; Was life-threatening; Required inpatient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect. The investigator assessed the causality/relationship between study treatment and each AE, and assessed the severity of each AE according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). Cornea and retina AEs were defined by Standardized Medical Dictionary for Regulatory Activities Queries (SMQs) of corneal disorders and retinal disorders (broad).

Full Information

First Posted
September 14, 2018
Last Updated
December 15, 2022
Sponsor
Five Prime Therapeutics, Inc.
Collaborators
Zai Lab (Shanghai) Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03694522
Brief Title
A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
Acronym
FIGHT
Official Title
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
September 14, 2018 (Actual)
Primary Completion Date
September 23, 2020 (Actual)
Study Completion Date
May 13, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Five Prime Therapeutics, Inc.
Collaborators
Zai Lab (Shanghai) Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of the Phase 2 part of the study is to evaluate the efficacy of bemarituzumab (FPA144), a targeted antibody, in combination with modified FOLFOX6 compared to placebo in combination with modified FOLFOX6 in participants with advanced gastrointestinal cancer.
Detailed Description
Study FPA144-004 is a phase 1/2, multicenter, global, double-blind, randomized, controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of bemarituzumab in combination with mFOLFOX6, compared with placebo in combination with mFOLFOX6, in adults with unresectable, locally advanced, or metastatic gastric cancer including cancer of the gastroesophageal junction (GEJ). This study includes a Phase 1 safety run-in portion and a Phase 2 portion. The Phase 1 safety run-in is an open-label dose-escalation of bemarituzumab + mFOLFOX6 in patients with GI tumors (not FGFR2 selected) that is reported separately (NCT03343301). The Phase 2 portion of the study (to follow the Phase 1 safety run-in) is described in this record.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Double blinded (participant, treating physician)
Allocation
Randomized
Enrollment
155 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bemarituzumab + mFOLFOX6
Arm Type
Experimental
Arm Description
Participants received 15 mg/kg bemarituzumab administered every 2 weeks (Q2W) with a single additional bemarituzumab 7.5 mg/kg dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
Arm Title
Placebo + mFOLFOX6
Arm Type
Placebo Comparator
Arm Description
Participants received placebo for bemarituzumab administered every 2 weeks with a single additional placebo dose on cycle 1 day 8. Participants also received mFOLFOX6 chemotherapy administered Q2W. Treatment continued until unacceptable toxicity, disease progression, or death.
Intervention Type
Biological
Intervention Name(s)
Bemarituzumab
Other Intervention Name(s)
FPA144, AMG 552
Intervention Description
Administered by intravenous infusion over approximately 30 minutes
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Administered by intravenous infusion over approximately 30 minutes
Intervention Type
Drug
Intervention Name(s)
Modified FOLFOX6
Other Intervention Name(s)
mFOLFOX6
Intervention Description
mFOLFOX6 regimen consists of the following: Oxaliplatin 85 mg/m² IV infusion over 120 minutes Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours
Primary Outcome Measure Information:
Title
Progression-Free Survival (PFS)
Description
PFS was defined as time from randomization until the date of radiographic disease progression based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or death from any cause, whichever came first. PFS was analyzed using Kaplan-Meier methods. Participants with no progression or death, or who started new anticancer therapy before documented progression or death without documented progression, or who had ≥ 2 consecutive missing tumor assessments before documented progression or death without documented progression were censored on the date of last adequate tumor assessment. Participants with no baseline tumor assessment, were censored at the date of randomization. The primary efficacy analysis was pre-specified to be conducted after at least 84 PFS events were observed.
Time Frame
From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.
Secondary Outcome Measure Information:
Title
Overall Survival (OS)
Description
OS is defined as time from randomization until death from any cause. Participants who were lost to follow-up or did not have a date of death were censored at the last date that they were known to be alive. Participants with confirmed death or alive status after the data cutoff date were censored at the data cutoff date. Median OS was estimated using a Kaplan-Meier analysis.
Time Frame
From randomization until the primary analysis data cut-off date of 23 September 2020; median time on follow-up was 10.9 months.
Title
Overall Response Rate (ORR)
Description
Tumor response assessment was performed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines. ORR is defined as the percentage of participants who achieved a best overall response (BOR) of either complete response (CR) or partial response (PR) based on investigator assessment of tumor lesions per RECIST v1.1. CR was defined as the disappearance of all lesions except lymph node short axis < 10 mm; PR was defined as a ≥ 30% reduction in sum of diameters in target lesions.
Time Frame
Tumor assessments were performed every 8 weeks until 12 months and then every 12 weeks thereafter until disease progression or additional anticancer therapy was initiated; the median duration of follow-up time was 10.9 months.
Title
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Description
TEAEs are defined as adverse events (AEs) that started or worsened from the start of study drug to 28 days after permanent discontinuation of study drug. A serious AE is defined as any untoward medical occurrence that: Resulted in death; Was life-threatening; Required inpatient hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect. The investigator assessed the causality/relationship between study treatment and each AE, and assessed the severity of each AE according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version 5.0 on a scale from mild (Grade 1), moderate (Grade 2), severe (Grade 3), life-threatening (Grade 4), or death due to the AE (Grade 5). Cornea and retina AEs were defined by Standardized Medical Dictionary for Regulatory Activities Queries (SMQs) of corneal disorders and retinal disorders (broad).
Time Frame
From first dose of study drug to 28 days after last dose of study drug. Actual median (min, max) duration of treatment emergent period was 29 (4.1, 157) weeks in the bemarituzumab + mFOLFOX6 group and 28 (4.3, 133) weeks in the placebo + mFOLFOX6 group.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Histologically documented gastric or gastroesophageal junctional adenocarcinoma (not amenable to curative therapy) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 Adequate hematological, liver and kidney function. Measurable or non-measurable, but evaluable disease using RECIST v1.1 Fibroblast growth factor receptor 2b (FGFR2b) overexpression as determined by a centrally performed immunohistochemistry tissue test and/or FGFR2 gene amplification as determined by a centrally performed circulating tumor deoxyribonucleic acid (ctDNA) blood based assay Candidate for mFOLFOX6 chemotherapy Key Exclusion Criteria: Untreated or symptomatic central nervous system (CNS) metastases Clinically significant cardiac disease, Peripheral sensory neuropathy >/= Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 Active infection requiring systemic treatment Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, or known active or chronic hepatitis B or C infection Prior treatment with any selective inhibitor of the fibroblast growth factor (FGF)-FGFR pathway Known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer Known positivity for human epidermal growth factor receptor 2 (HER2) Women who are pregnant or breastfeeding Note: Other protocol defined Inclusion/Exclusion criteria may apply
Facility Information:
Facility Name
University of Arizona Cancer Center
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Facility Name
The Oncology Institute of Tuscon
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85745
Country
United States
Facility Name
Marin Cancer Care, Inc-California Cancer Care A Medical Group, Inc
City
Greenbrae
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
Sutter Medical Group
City
Sacramento
State/Province
California
ZIP/Postal Code
95816
Country
United States
Facility Name
UCLA Medical Centre - Santa Monica Hematology and Oncology
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Innovative Clinical Research Institute (ICRI)
City
Whittier
State/Province
California
ZIP/Postal Code
90603
Country
United States
Facility Name
Yale Cancer Center
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06519
Country
United States
Facility Name
Hartford Healthcare Cancer Institute at The Hospital of Central Connecticut
City
Plainville
State/Province
Connecticut
ZIP/Postal Code
06062
Country
United States
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Facility Name
Northwestern Medicine Cancer Center Warrenville
City
Warrenville
State/Province
Illinois
ZIP/Postal Code
60555
Country
United States
Facility Name
University of Kansas Medical Center
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Facility Name
Oschsner Clinic Foundation
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70121
Country
United States
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
University of Michigan Health System
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Facility Name
Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Josephine Ford Cancer Center-Henry Ford Cancer Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Summit Medical Group. Morristown Oncology
City
Morristown
State/Province
New Jersey
ZIP/Postal Code
07960
Country
United States
Facility Name
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Stony Brook Cancer Center
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Facility Name
Westchester Institute For Treatment Of Cancer & Blood Disorders
City
White Plains
State/Province
New York
ZIP/Postal Code
10601
Country
United States
Facility Name
UNC- Chapel Hill
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
FirstHealth Outpatient Cancer Center
City
Pinehurst
State/Province
North Carolina
ZIP/Postal Code
28374
Country
United States
Facility Name
St. Luke's Physician Group - St. Luke's Cancer Care Associates
City
Bethlehem
State/Province
Pennsylvania
ZIP/Postal Code
18015
Country
United States
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29435
Country
United States
Facility Name
Tennessee Cancer Specialists
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37909
Country
United States
Facility Name
Arlington Cancer Center
City
Arlington
State/Province
Texas
ZIP/Postal Code
76012
Country
United States
Facility Name
Utah Cancer Specialists (Intermountain Hematology - Oncology Associates) UCS Cancer Center
City
S. Salt Lake
State/Province
Utah
ZIP/Postal Code
84106
Country
United States
Facility Name
Virginia Mason Seattle Main Clinic
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Facility Name
Chris O'brien Lifehouse
City
Camperdown
Country
Australia
Facility Name
The Townsville Hospital
City
Douglas
Country
Australia
Facility Name
Sydney Adventist Hospital
City
Wahroonga
Country
Australia
Facility Name
AZ Sint Jan
City
Brugge
Country
Belgium
Facility Name
CH de l'Ardenne
City
Libramont
ZIP/Postal Code
6800
Country
Belgium
Facility Name
CHC Clinique Saint-Joseph
City
Liege
ZIP/Postal Code
04000
Country
Belgium
Facility Name
CHU UCL Namur, site Godinne
City
Yvoir
ZIP/Postal Code
05530
Country
Belgium
Facility Name
Anhui Provincial Cancer Hospital
City
Hefei
State/Province
Anhui
ZIP/Postal Code
230031
Country
China
Facility Name
Shiyan Taihe Hospital
City
Shiyan
State/Province
Hubei
ZIP/Postal Code
442000
Country
China
Facility Name
Wuhan Union Hospital of China
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430000
Country
China
Facility Name
The 81st Hospital of Chinese PLA
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210002
Country
China
Facility Name
Beijing Cancer Hospital
City
Beijing
ZIP/Postal Code
100412
Country
China
Facility Name
Chinese PLA General Hospital
City
Beijing
Country
China
Facility Name
The First Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130021
Country
China
Facility Name
Sino Japanese Friendship Hospital of Jilin University
City
Changchun
ZIP/Postal Code
130033
Country
China
Facility Name
Hunan Cancer Hospital
City
Changsha
ZIP/Postal Code
410006
Country
China
Facility Name
Xiangya Hospital of Central South University
City
Changsha
Country
China
Facility Name
Chongqing Daping Hospital
City
Chongqing
ZIP/Postal Code
400000
Country
China
Facility Name
Fujian Cancer Hospital
City
Fuzhou
ZIP/Postal Code
350014
Country
China
Facility Name
The First Affiliated Hospital, Zhejiang University
City
Hangzhou
ZIP/Postal Code
310003
Country
China
Facility Name
Sir Run Run Shaw Hospital
City
Hangzhou
Country
China
Facility Name
Zhejiang Cancer Hospital
City
Hangzhou
Country
China
Facility Name
Harbin Medical University Cancer Hopsital
City
Harbin
Country
China
Facility Name
Nanton Tumor Hospital
City
Nantong
Country
China
Facility Name
Shanghai East Hospital
City
Shanghai
ZIP/Postal Code
200123
Country
China
Facility Name
Fudan University Shanghai Cancer Center
City
Shanghai
ZIP/Postal Code
210032
Country
China
Facility Name
Ruijin Hospital Affiliated to Shanghai Jiatong University School of Medicine
City
Shanghai
Country
China
Facility Name
Cancer Hospital of Shantou University Medical College
City
Shantou
ZIP/Postal Code
515041
Country
China
Facility Name
Liaoning Cancer Hospital
City
Shenyang
ZIP/Postal Code
110042
Country
China
Facility Name
Fourth Hospital of Hebei Medical University
City
Shijiazhuang
Country
China
Facility Name
The Second Affiliated Hospital of Soochow University
City
Suzhou
ZIP/Postal Code
215004
Country
China
Facility Name
Tianjin Medical University Cancer Institute and Hospital
City
Tianjin
ZIP/Postal Code
300060
Country
China
Facility Name
Henan Cancer Hospital
City
Zhengzhou
ZIP/Postal Code
450008
Country
China
Facility Name
CHRU Jean MINJOZ
City
Besançon
ZIP/Postal Code
25000
Country
France
Facility Name
Chu Morvan - Institut de Cancerologie
City
Brest
Country
France
Facility Name
Hopital Nord France Comte - Site Le Mittan
City
Montbéliard
ZIP/Postal Code
25200
Country
France
Facility Name
Polyclinique de Gentilly
City
Nancy
Country
France
Facility Name
CHU de Saint Etienne
City
Saint-Étienne
ZIP/Postal Code
42055
Country
France
Facility Name
Centre de Radiotherapie - Clinique Sainte Anne
City
Strasbourg
ZIP/Postal Code
67000
Country
France
Facility Name
Centre Paul Strauss
City
Strasbourg
Country
France
Facility Name
Klinik fur Innere Medizin, Shwerpunkt Gastroenterologie, Hamatologie, Onkologie, Nephrologie
City
Berlin
ZIP/Postal Code
12559
Country
Germany
Facility Name
Stadtisches Klinikum Braunschweig
City
Braunschweig
ZIP/Postal Code
38114
Country
Germany
Facility Name
Krankenhaus Nordwest gGmbH, Institut fur Klinisch-Onkologische Forschung
City
Frankfurt am Main
ZIP/Postal Code
60488
Country
Germany
Facility Name
Klinikum Ludwigsburg
City
Ludwigsburg
ZIP/Postal Code
71640
Country
Germany
Facility Name
Universitatsmedizin Manheim, II. Medizinische Klinik
City
Mannheim
Country
Germany
Facility Name
Klinikum Ostalb, Stauferklinikum Schwabisch Gmund, Zentrum fur Innere Medizin
City
Mutlangen
Country
Germany
Facility Name
Kliniken Nordoberpfalz AG, Klinikum Weiden, Medizinische Klinik I
City
Oberpfalz
ZIP/Postal Code
92637
Country
Germany
Facility Name
National Institute of Oncology
City
Budapest
ZIP/Postal Code
1122
Country
Hungary
Facility Name
Del-Pesti Centrumkorhaz - Orszangos Hematologiai es Infektologiai Intezet, Onkologiai Osztaly
City
Budapest
Country
Hungary
Facility Name
Sugarterapias es Klinikai Onkologaiai Intezet B-A-Z Megyei Korhaz
City
Miskolc
Country
Hungary
Facility Name
Josa Andras Teaching Hospital
City
Nyíregyháza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
University of Pecs, Clinic of Oncotherapy
City
Pecs
ZIP/Postal Code
7624
Country
Hungary
Facility Name
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet
City
Szolnok
ZIP/Postal Code
5000
Country
Hungary
Facility Name
AOU Ospedall Riuniti Umberto
City
Ancona
ZIP/Postal Code
60020
Country
Italy
Facility Name
AO "S.G. Moscati"
City
Avellino
Country
Italy
Facility Name
Centro di Riferimento Oncologico
City
Aviano
ZIP/Postal Code
33081
Country
Italy
Facility Name
Azienda Ospedaliera Spedali Civili di Brescia-Universita degli Studi Di Brescia
City
Brescia
Country
Italy
Facility Name
Istituto di Ricovero e Cura a Carattere Scientifico - IRCCS di Candiolo
City
Candiolo
ZIP/Postal Code
10060
Country
Italy
Facility Name
Azienda Socio-Sanitaria Territoriale di Cremona
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
Azienda Ospedaliero Universitaria Caregg - I S.O.D. Oncologia Medica
City
Firenze
Country
Italy
Facility Name
Ospedale Policlinico S. Martino
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Ospedale Generale Mater Salutis" - Azienda ULSS n. 21 di Legnago
City
Legnago
ZIP/Postal Code
37045
Country
Italy
Facility Name
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
City
Meldola
ZIP/Postal Code
47014
Country
Italy
Facility Name
Istituto Europeo di Oncologia
City
Milan
ZIP/Postal Code
20141
Country
Italy
Facility Name
Servizio Oncologia Medica ed Ematologia, AOU dell'Universita
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
Fondazione Irccs Policlinico San Matteo
City
Pavia
Country
Italy
Facility Name
Azienda Ospedaliera Universitaria Pisana
City
Pisa
Country
Italy
Facility Name
Policlinico Universitario Campus Bio-Medico di Roma
City
Roma
Country
Italy
Facility Name
Fondazione IRCSS Casa Sollievo Della Sofferenza
City
San Giovanni Rotondo
Country
Italy
Facility Name
ASST della Valtellina e dell'Alto Lario - PO di Sondrio
City
Sondrio
Country
Italy
Facility Name
A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
City
Torino
Country
Italy
Facility Name
Azienda Sanitaria Universitaria Integrata de Udine
City
Udine
ZIP/Postal Code
33100
Country
Italy
Facility Name
National Cancer Center Hospital East
City
Kashiwa
State/Province
Chiba
ZIP/Postal Code
277-8577
Country
Japan
Facility Name
Kagawa University Hospital
City
Kita-gun
State/Province
Kagawa
ZIP/Postal Code
761-0793
Country
Japan
Facility Name
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
City
Bunkyō-Ku
Country
Japan
Facility Name
Hiroshima Citizens Hospital
City
Hiroshima
ZIP/Postal Code
730-8518
Country
Japan
Facility Name
St. Marianna University School of Medicine Hospital
City
Kawasaki
ZIP/Postal Code
216-8511
Country
Japan
Facility Name
Japan Community Health Care Organization Kyushu Hospital
City
Kitakyushu
Country
Japan
Facility Name
The Cancer Institute Hospital of JFCR
City
Koto-Ku
Country
Japan
Facility Name
Niigata Cancer Center Hospital
City
Niigata
ZIP/Postal Code
951-8566
Country
Japan
Facility Name
Hyogo College of Medicine College Hospital
City
Nishinomiya
ZIP/Postal Code
663-8501
Country
Japan
Facility Name
Osaka General Medical Center
City
Osaka
ZIP/Postal Code
558-8558
Country
Japan
Facility Name
Osaka Medical College Hospital
City
Osaka
ZIP/Postal Code
569-8686
Country
Japan
Facility Name
Gangnam Severance Hospital, Yonsei University Health System
City
Seoul
State/Province
Gangnam
ZIP/Postal Code
06273
Country
Korea, Republic of
Facility Name
Hallym University Sacred Heart Hospital
City
Anyang
State/Province
Gyeonggi-do
ZIP/Postal Code
14068
Country
Korea, Republic of
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Gyeonggi
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Ajou University Hospital
City
Suwon
State/Province
Gyeonggi
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Chonbuk National University Hospital
City
Jeonju
State/Province
Jeollabuk-do
ZIP/Postal Code
54907
Country
Korea, Republic of
Facility Name
Gachon University Gil Medical Center
City
Incheon
State/Province
Namdong-gu
ZIP/Postal Code
21565
Country
Korea, Republic of
Facility Name
Kyungpook National University Chilgok Hospital
City
Daegu
State/Province
North Gyeongsang
Country
Korea, Republic of
Facility Name
Dong-A University Hospital
City
Busan
ZIP/Postal Code
49201
Country
Korea, Republic of
Facility Name
Chungnam National University Hospital (CNUH)
City
Daejeon
ZIP/Postal Code
35015
Country
Korea, Republic of
Facility Name
Korea University Anam Hospital
City
Seoul
ZIP/Postal Code
02841
Country
Korea, Republic of
Facility Name
Yonsei University Health System
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Kangbuk Samsung Hospital
City
Seoul
ZIP/Postal Code
04514
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
The Catholic University of Korea, Seoul St. Mary's Hospital
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Facility Name
Korea University Guro Hospital
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
3080
Country
Korea, Republic of
Facility Name
Beskidzkie Centrum Onkologii - Szpital Miejski im. Jana Pawla II w Bielsku-Bialej
City
Bielsko-Biala
ZIP/Postal Code
43-300
Country
Poland
Facility Name
Szpital Specjalistyczny w Brzozowie, Podkarpacki Osrodek Onkologiczny
City
Brzozów
ZIP/Postal Code
36-200
Country
Poland
Facility Name
Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie
City
Lublin
Country
Poland
Facility Name
SP ZOZ Ministerstwa Spraw Wewnetrznych z Warminsko - Mazurskim Centrum Onkologii
City
Olsztyn
ZIP/Postal Code
10-228
Country
Poland
Facility Name
Europejskie Centrum Zdrowia Otwock Szpital im. F. Chopina
City
Otwock
ZIP/Postal Code
05-400
Country
Poland
Facility Name
Lekarz Beata Madej Mruk I Partner. Spolka Partnerska Oddzial nr 1 w Rzesowie
City
Rzeszów
ZIP/Postal Code
35-021
Country
Poland
Facility Name
Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny Ministerstwa Obronty Narodowej
City
Warszawa
ZIP/Postal Code
04-141
Country
Poland
Facility Name
Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie Klinika Onkologi I Radioterapii
City
Warszawa
Country
Poland
Facility Name
Centro Hospitalar do Baixo Vouga, EPE
City
Aveiro
ZIP/Postal Code
3814-501
Country
Portugal
Facility Name
Hospital de Braga
City
Braga
ZIP/Postal Code
4710-243
Country
Portugal
Facility Name
Hospital Senhora Da Oliveira EPE
City
Guimarães
Country
Portugal
Facility Name
Centro Hospitalar Universitario do Porto E.P.E
City
Porto
ZIP/Postal Code
4099-011
Country
Portugal
Facility Name
Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E
City
Porto
Country
Portugal
Facility Name
Centro Hospitalar de Entre o Douro e Vouga EPE
City
Santa Maria Da Feira
Country
Portugal
Facility Name
Unidade Local de Saude de Matosinhos EPE
City
Senhora Da Hora
Country
Portugal
Facility Name
Institutul Clinic Fundeni - Clinica Pediatrie
City
Bucharest
ZIP/Postal Code
022328
Country
Romania
Facility Name
S.C. Medisprof S.R.L
City
Cluj Napoca
ZIP/Postal Code
400641
Country
Romania
Facility Name
Institutul Oncologic, Prof. Dr. I. Chiricuta Cluj-Napoca
City
Cluj-Napoca
ZIP/Postal Code
400015
Country
Romania
Facility Name
Spitalul Clinic Judetean de Urgenta ,,Sf. Apostol Andrei" Constanta, Clinica Oncologie Medicala
City
Constanţa
ZIP/Postal Code
900591
Country
Romania
Facility Name
S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala
City
Craiova
ZIP/Postal Code
200347
Country
Romania
Facility Name
SC Oncolab SRL, Oncologie
City
Craiova
ZIP/Postal Code
200385
Country
Romania
Facility Name
S.C. Oncocenter Oncologie Clinica S.R.L
City
Timisoara
ZIP/Postal Code
300166
Country
Romania
Facility Name
Complejo Hospitalario Universitario A Coruna
City
A Coruña
Country
Spain
Facility Name
Hospital Universitario Fundacion Alcorcon
City
Alcorcon
Country
Spain
Facility Name
Hospital del Mar
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital Duran I Reynals - Instituto Catalan de Oncologia
City
Barcelona
ZIP/Postal Code
08908
Country
Spain
Facility Name
Hospital de la Santa Creu I Sant Pau
City
Barcelona
Country
Spain
Facility Name
Hospital General de Catalunya
City
Barcelona
Country
Spain
Facility Name
Institut Catala d'Oncologia - Hospital Doctor Josep Trueta
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Hospital Universitari Arnau de Vilanova
City
Lleida
Country
Spain
Facility Name
Hospital Universitario Fundacion Jimenez Diaz
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario HM Sanchinarro
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Hospital General Universitario Gregorio Maranon
City
Madrid
Country
Spain
Facility Name
Hospital Universitario Puerta de Hierro Majadahonda
City
Majadahonda
Country
Spain
Facility Name
Clinica Universidad de Navarra
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Complejo Hospital De Navarra
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Corporacio Sanitaria Parc Tauli
City
Sabadell
Country
Spain
Facility Name
Hosptial Universitario Virgen Macarena
City
Servilla
ZIP/Postal Code
41009
Country
Spain
Facility Name
Hospital Universitario Mutua de Terrassa
City
Terrassa
ZIP/Postal Code
08221
Country
Spain
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
Faculty of Medicine, Chulalongkorn University
City
Bankok
Country
Thailand
Facility Name
Chiangrai Prachanukroh Hospital
City
Chiang Rai
Country
Thailand
Facility Name
Faculty of Medicine, Prince of Sonkla University
City
Hat Yai
ZIP/Postal Code
90110
Country
Thailand
Facility Name
Khon Kaen Hospital
City
Khon Kaen
Country
Thailand
Facility Name
Lampang Cancer Hospital
City
Lampang
Country
Thailand
Facility Name
Cukurova University Faculty of Medicine Paediatric Nephrology
City
Adana
Country
Turkey
Facility Name
Hacettepe Universitesi Tip Fakultesi
City
Ankara
ZIP/Postal Code
06100
Country
Turkey
Facility Name
Ankara Oncology Education and Research Hospital
City
Ankara
ZIP/Postal Code
06200
Country
Turkey
Facility Name
Ondokuz Mayis University Medicine Faculty
City
Atakum
ZIP/Postal Code
55200
Country
Turkey
Facility Name
Adnan Menderes Universitesi Uygulama ve Arastirma Hastanesi
City
Aydin
ZIP/Postal Code
09100
Country
Turkey
Facility Name
Uludag Universitesi Tip Fakultesi
City
Bursa
ZIP/Postal Code
16059
Country
Turkey
Facility Name
Gaziantep Universitesi Tip Fakultesi, Sahinbey Onkoloji Hastanesi
City
Gaziantep
Country
Turkey
Facility Name
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
City
Istanbul
ZIP/Postal Code
34093
Country
Turkey
Facility Name
Istanbul Madeniyet Universitesi Tip Fakultesi
City
Istanbul
Country
Turkey
Facility Name
Istanbul University Cerrahpasa Medical Faculty
City
Istanbul
Country
Turkey
Facility Name
Medical Park Izmir Hastanesi
City
Izmir
ZIP/Postal Code
35575
Country
Turkey
Facility Name
Ege University Hopsital
City
Izmir
Country
Turkey
Facility Name
Kocaeli Universitesi Tip Fakultesi
City
Kocaeli
ZIP/Postal Code
41380
Country
Turkey
Facility Name
Inonu Universitesi Tip Fakultesi Turgut Ozal Tip Merkezi
City
Malatya
ZIP/Postal Code
44300
Country
Turkey
Facility Name
Yuzuncuyil Universitesi Tip Fakultesi
City
Van
ZIP/Postal Code
65080
Country
Turkey
Facility Name
Ninewells Hospital and Medical School
City
Dundee
ZIP/Postal Code
DD198Y
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36244398
Citation
Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Nov;23(11):1430-1440. doi: 10.1016/S1470-2045(22)00603-9. Epub 2022 Oct 14.
Results Reference
derived
PubMed Identifier
32965540
Citation
Xiang H, Liu L, Gao Y, Ahene A, Macal M, Hsu AW, Dreiling L, Collins H. Population pharmacokinetic analysis of phase 1 bemarituzumab data to support phase 2 gastroesophageal adenocarcinoma FIGHT trial. Cancer Chemother Pharmacol. 2020 Nov;86(5):595-606. doi: 10.1007/s00280-020-04139-4. Epub 2020 Sep 23.
Results Reference
derived

Learn more about this trial

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

We'll reach out to this number within 24 hrs